Hormone replacement therapy in postmenopausal women.

[1]  G. Emons,et al.  Hormone Replacement Therapy and Endometrial Cancer , 2004, Oncology Research and Treatment.

[2]  R. Dluhy,et al.  Rethinking postmenopausal hormone therapy. , 2003, The New England journal of medicine.

[3]  R. J. Cersosimo.  Tamoxifen for Prevention of Breast Cancer , 2003, The Annals of pharmacotherapy.

[4]  E. Vittinghoff,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[5]  M. Enserink.  U.K. Hormone Trial to Pause for Review , 2002, Science.

[6]  H. Nelson,et al.  Hormone Replacement Therapy and Risk of Venous Thromboembolism , 2002 .

[7]  M. Enserink.  Despite Safety Concerns, U.K. Hormone Study to Proceed , 2002, Science.

[8]  P. Hartge,et al.  Menopausal hormone replacement therapy and risk of ovarian cancer. , 2002, JAMA.

[9]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[10]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[11]  Stephen B. Hulley,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II) , 2002 .

[12]  P. Delmas,et al.  Treatment of postmenopausal osteoporosis , 2002, The Lancet.

[13]  E. Weiderpass,et al.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. , 2002, Journal of the National Cancer Institute.

[14]  E. Barrett-Connor,et al.  Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial , 2002 .

[15]  P. Newcomb,et al.  Hormone replacement therapy in relation to breast cancer. , 2002, JAMA.

[16]  E. Vittinghoff,et al.  Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. , 2002, JAMA.

[17]  D. Herrington,et al.  Cardiovascular Trials of Estrogen Replacement Therapy , 2001, Annals of the New York Academy of Sciences.

[18]  C. Viscoli,et al.  A clinical trial of estrogen-replacement therapy after ischemic stroke. , 2001, The New England journal of medicine.

[19]  S. Davis.  Phytoestrogen therapy for menopausal symptoms? , 2001, BMJ : British Medical Journal.

[20]  K. Schenck-Gustafsson,et al.  Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 2001, Circulation.

[21]  F. Grodstein,et al.  Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study , 2001, Annals of Internal Medicine.

[22]  V. Fuster,et al.  Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. , 2001, Journal of the American College of Cardiology.

[23]  G. Bachmann,et al.  Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. , 2001, Fertility and sterility.

[24]  S. Cummings,et al.  Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). , 2001, The American journal of medicine.

[25]  M. Taskinen,et al.  Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women , 2001, Thrombosis and Haemostasis.

[26]  M. Thun,et al.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. , 2001, JAMA.

[27]  A. Maclennan,et al.  Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. , 2001 .

[28]  A. LaCroix,et al.  Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. , 2001, JAMA.

[29]  J. Hsia,et al.  Postmenopausal Hormone Therapy and Risk of Stroke: The Heart and Estrogen-progestin Replacement Study (HERS) , 2001, Circulation.

[30]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[31]  P. Goss,et al.  Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.

[32]  A. Maclennan,et al.  Oral oestrogen replacement therapy versus placebo for hot flushes. , 2001, The Cochrane database of systematic reviews.

[33]  M. Whitehead,et al.  Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? , 2001, Climacteric : the journal of the International Menopause Society.

[34]  F. Speizer,et al.  A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease , 2000, Annals of Internal Medicine.

[35]  Debra L Barton,et al.  Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial , 2000, The Lancet.

[36]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[37]  P. Flynn,et al.  Oral Clonidine in Postmenopausal Patients with Breast Cancer Experiencing Tamoxifen-Induced Hot Flashes: A University of Rochester Cancer Center Community Clinical Oncology Program Study , 2000, Annals of Internal Medicine.

[38]  P. Austin,et al.  Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[39]  Hein Df.  Osteoporosis. An overview of the National Osteoporosis Foundation clinical practice guide. , 2000 .

[40]  C. Gajdos,et al.  Breast Cancer Diagnosed During Hormone Replacement Therapy , 2000, Obstetrics and gynecology.

[41]  G. Koukoulis.  Hormone Replacement Therapy and Breast Cancer Risk , 2000, Annals of the New York Academy of Sciences.

[42]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[43]  R. Ross,et al.  RESPONSE: re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin , 2000, Journal of the National Cancer Institute.

[44]  R. Hoover,et al.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. , 2000, JAMA.

[45]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[46]  Stehouwer,et al.  Short‐term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules , 1999, European journal of clinical investigation.

[47]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[48]  C. Webb,et al.  Estrogen hits the surface , 1999, Nature Medicine.

[49]  P. Sandset,et al.  Hormone Replacement Therapy with Estradiol and Risk of Venous Thromboembolism , 1999, Thrombosis and Haemostasis.

[50]  N. Hacker,et al.  Hormone replacement therapy and risk of epithelial ovarian cancer , 1999, British Journal of Cancer.

[51]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[52]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[53]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[54]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[55]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[56]  M. Mendelsohn,et al.  Protective effects of estrogen on the cardiovascular system. , 1999, The American journal of cardiology.

[57]  C. Stehouwer,et al.  Increased C-reactive Protein Levels during Short-term Hormone Replacement Therapy in Healthy Postmenopausal Women , 1999, Thrombosis and Haemostasis.

[58]  Nanette Santoro,et al.  Where Are We Going , 1999 .

[59]  F. Grodstein,et al.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. , 1999, The American journal of medicine.

[60]  V. Hasselblad,et al.  Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. , 1999, Obstetrics and gynecology.

[61]  Paul Cleary,et al.  Use of Hormone Replacement Therapy by Postmenopausal Women in the United States , 1999, Annals of Internal Medicine.

[62]  V. Beral,et al.  Hormonal therapy for menopause and ovarian cancer in a collaborative re‐analysis of European studies , 1999, International journal of cancer.

[63]  S. Cummings,et al.  Elevated Serum Estradiol and Testosterone Concentrations Are Associated with a High Risk for Breast Cancer , 1999, Annals of Internal Medicine.

[64]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[65]  Susan R. Johnson,et al.  Symptom Relief and Side Effects of Postmenopausal Hormones: Results From the Postmenopausal Estrogen/Progestin Interventions Trial , 1998, Obstetrics and gynecology.

[66]  B. Ettinger,et al.  Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. , 1998, The American journal of managed care.

[67]  J. Cuzick,et al.  Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  D. Petitti.  Hormone replacement therapy and heart disease prevention: experimentation trumps observation. , 1998, JAMA.

[69]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[70]  M. Segal,et al.  Estradiol Increases Dendritic Spine Density by Reducing GABA Neurotransmission in Hippocampal Neurons , 1998, The Journal of Neuroscience.

[71]  R. Ross,et al.  Atherosclerosis is an Inflammatory Disease , 1998 .

[72]  L. García-Rodríguez,et al.  Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. , 1998, American journal of epidemiology.

[73]  A. LaCroix,et al.  Breast cancer and hormone replacement therapy , 1997, The Lancet.

[74]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[75]  W. Spitzer,et al.  First-time use of newer oral contraceptives and the risk of venous thromboembolism. , 1997, Contraception.

[76]  K. Ramanathan,et al.  Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. , 1997, American Journal of Cardiology.

[77]  J. Castellsagué,et al.  Hormone replacement therapy and risk of venous thromboembolism: population based case-control study , 1997, BMJ.

[78]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[79]  J. Rossouw.  Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon. , 1996, Circulation.

[80]  S. Cummings,et al.  Bone Mineral Density and Risk of Breast Cancer in Older Women: The Study of Osteoporotic Fractures , 1996 .

[81]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[82]  J. Manson,et al.  Prospective study of exogenous hormones and risk of pulmonary embolism in women , 1996, The Lancet.

[83]  M. Vessey,et al.  Case-control study of venous thromboembolism risk in users of hormone replacement therapy , 1996, The Lancet.

[84]  K. Newton,et al.  Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens , 1996, The Lancet.

[85]  J. Carson,et al.  Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.

[86]  J. Manson,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[87]  K. Hatch,et al.  Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. , 1996, Gynecologic oncology.

[88]  R. Santen.  Long-term tamoxifen therapy: can an antagonist become an agonist? , 1996, The Journal of clinical endocrinology and metabolism.

[89]  Susan R. Johnson,et al.  Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1996, JAMA.

[90]  C. Longcope,et al.  Serum gonadotropins and steroid hormones and the development of ovarian cancer. , 1995, JAMA.

[91]  S. Chou.  Antilymphoblastic globulin in renal transplant patients: no allergic reactions: a correction. , 1995, JAMA.

[92]  H. Semlitsch,et al.  Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression , 1995, Psychopharmacology.

[93]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[94]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[95]  D. Barlow,et al.  Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? , 1994, The Lancet.

[96]  J. O'fallon,et al.  Megestrol acetate for the prevention of hot flashes. , 1994, The New England journal of medicine.

[97]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[98]  D. Petitti.  Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? , 1994, Annals of epidemiology.

[99]  T. Hamilton,et al.  Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells , 1994, Molecular and Cellular Endocrinology.

[100]  G. Colditz,et al.  Postmenopausal Hormone Use and Cholecystectomy in a Large Prospective Study , 1994, Obstetrics and gynecology.

[101]  J. Madans,et al.  Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. , 1993, Archives of internal medicine.

[102]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[103]  A S Whittemore,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[104]  A S Whittemore,et al.  Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12 U.S. Case-Control Studies. VI. Nonepithelial Cancers among Adults , 1992, Epidemiology.

[105]  E. Barrett-Connor,et al.  Estrogen replacement therapy and the risk of venous thrombosis. , 1992, The American journal of medicine.

[106]  S. Shapiro,et al.  Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. , 1991, American journal of epidemiology.

[107]  E. Barrett-Connor.  Postmenopausal estrogen and prevention bias. , 1991, Annals of internal medicine.

[108]  D. Mirvis,et al.  Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. , 1990, Archives of internal medicine.

[109]  S. Manuck,et al.  Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. , 1990, Arteriosclerosis.

[110]  C. Viscoli,et al.  Treatment adherence and risk of death after a myocardial infarction , 1990, The Lancet.

[111]  S. Shapiro,et al.  Noncontraceptive estrogen use and epithelial ovarian cancer. , 1989, American journal of epidemiology.

[112]  G. Reynolds,et al.  INCREASED BRAIN 3-HYDROXYKYNURENINE IN HUNTINGTON'S DISEASE , 1989, The Lancet.

[113]  V. Beral,et al.  Risk factors for ovarian cancer: a case-control study. , 1989, British Journal of Cancer.

[114]  M. Pike,et al.  STROKE PREVENTION AND OESTROGEN REPLACEMENT THERAPY , 1989, The Lancet.

[115]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[116]  R. Hoover,et al.  Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. , 1989, BMJ.

[117]  B. Sherwin,et al.  Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women , 1988, Psychoneuroendocrinology.

[118]  N. Weiss,et al.  Non-contraceptive estrogen use and the risk of gallstone disease in women. , 1988, American journal of public health.

[119]  P. Hartge,et al.  Menopause and ovarian cancer. , 1988, American journal of epidemiology.

[120]  B. Sherwin,et al.  Sex steroids and affect in the surgical menopause: a double-blind, cross-over study , 1985, Psychoneuroendocrinology.

[121]  D. Cramer,et al.  Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. , 1983, Journal of the National Cancer Institute.

[122]  L. Wallentin,et al.  SERUM FSH, LH AND OESTRONE LEVELS IN POSTMENOPAUSAL PATIENTS ON OESTROGEN THERAPY , 1978, British journal of obstetrics and gynaecology.

[123]  A. Entress,et al.  Letter: Continuous positive airways pressure in infants. , 1974, Lancet.

[124]  B. Barnes.  The Coronary Drug Project , 1972 .

[125]  C. Rosen.  Treatment of Postmenopausal Osteoporosis: An Evidence-Based Approach , 2004, Reviews in Endocrine and Metabolic Disorders.

[126]  A. Papavassiliou,et al.  Selective modulation of postmenopausal women , 2003, Cancer.

[127]  B. Rimer,et al.  The hormone therapy dilemma: women respond. , 2003, Journal of the American Medical Women's Association.

[128]  J. Hanfelt,et al.  A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  S. Shapiro,et al.  A case-control study of myocardial infarction in relation to use of estrogen supplements. , 1993, American journal of epidemiology.

[130]  S. Sidney,et al.  Increased risk of cholecystectomy in users of supplemental estrogen. , 1988, Gastroenterology.

[131]  D. Byar,et al.  Estrogen predisposes to cholecystectomy but not to stones. , 1982, Gastroenterology.

[132]  E. Kaplan.  Cancer of the ovary. , 1977, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[133]  G. Vanhulle,et al.  A Double-Blind Study into the Influence of Estriol on a Number of Psychological Tests in Post-menopausal Women , 1976 .